prikaz prve stranice dokumenta In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299
  Download
PDF 1.46 MB
master's thesis
In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299
Zagreb: University of Zagreb, Faculty of Science, 2020. urn:nbn:hr:217:798897
Vukić, Ana
University of Zagreb
Faculty of Science
Department of Biology

Institutional repository: Repository of the Faculty of Science

Cite this document

Vukić, A. (2020). In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299 (Master's thesis). Zagreb: University of Zagreb, Faculty of Science. Retrieved from https://urn.nsk.hr/urn:nbn:hr:217:798897

Vukić, Ana. "In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299." Master's thesis, University of Zagreb, Faculty of Science, 2020. https://urn.nsk.hr/urn:nbn:hr:217:798897

Vukić, Ana. "In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299." Master's thesis, University of Zagreb, Faculty of Science, 2020. https://urn.nsk.hr/urn:nbn:hr:217:798897

Vukić, A. (2020). 'In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299', Master's thesis, University of Zagreb, Faculty of Science, accessed 09 November 2024, https://urn.nsk.hr/urn:nbn:hr:217:798897

Vukić A. In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299 [Master's thesis]. Zagreb: University of Zagreb, Faculty of Science; 2020 [cited 2024 November 09] Available at: https://urn.nsk.hr/urn:nbn:hr:217:798897

A. Vukić, "In vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299", Master's thesis, University of Zagreb, Faculty of Science, Zagreb, 2020. Available at: https://urn.nsk.hr/urn:nbn:hr:217:798897

Metadata
TitleIn vitro testiranje združenog djelovanja kemoterapeutika i sintetskih liganada za receptor TLR7 u staničnoj liniji H1299
Title (english)In vitro testing of the chemoterapeutic activity in the presence of TLR7 receptor ligands in H1299 lineage
AuthorAna Vukić
MentorJelena Knežević (mentor)
MentorNada Oršolić (sumentor)
Committee memberNada Oršolić (predsjednik povjerenstva)
Committee memberInga Marijanović (član povjerenstva)
Committee memberMartina Šeruga Musić (član povjerenstva)
Committee memberSofia Ana Blažević (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Science
(Department of Biology)
Zagreb
Defense date and country2020-02-24, Croatia
Scientific / art field,
discipline and subdiscipline		NATURAL SCIENCES
Biology
Abstract
Karcinom pluća drugi je najčešće dijagnosticirani maligni tumor i najčešći uzrok smrti kod muškaraca i ţena u svijetu kada su u pitanju zloćudne bolesti. Pušenje predstavlja najveći rizik za njegov razvoj, ali nastanak tumora se moţe potaknuti i respiratornim bolestima te virusnim i bakterijskim infekcijama koje dovode do upalnih procesa koji mogu pogodovati razvoju tumora. UroĎeni imunosni sustav vaţan je za prvi odgovor organizma na infekciju patogenima, a u njegovoj aktivaciji ključnu ulogu imaju Toll-like receptori (TLR) koji prepoznaju patogenu pridruţene molekularne sljedove i potiču signalizaciju koja će dovesti do imunosnog odgovora. Endosomski receptor TLR7 aktiviraju jednolančane virusne RNA, ali i sintetski ligandi. Eksprimiran je u stanicama imunosnog sustava, ali i epitelnim te tumorskim stanicama. Cilj ovog diplomskog rada bio je istraţiti kako u in vitro uvjetima stanice metastatskog tumora pluća (H1299) odgovaraju na terapiju citostaticima (cisplatina, karboplatina i paklitaksel) i sintetskim ligandima za receptor TLR7 (resiquimod i imiquimod). Dokazana je ekspresija receptora TLR7 na razini mRNA i proteina u staničnoj liniji H1299 lančanom reakcijom polimerazom u stvarnom vremenu i westernskom metodom detekcije proteina. Pokazali smo da imiquimod u kombinaciji s cisplatinom i paklitakselom značajno smanjuje vijabilnost stanica, dok je utjecaj resiquimoda na citotoksičnost vrlo slab.
Abstract (english)
Lung cancer is the leading cause of cancer deaths and second most common diagnosed malignant tumor in both men and women. Smoking is the number one risk factor for lung cancer, but enviromental and genetic factors and respiratory diseases increase the chance of developing it as well. Bacterial and viral infections can lead to frequent inflammations linked to tumor progression. Innate immune system can be activated immediately after pathogen invasion. Activation of Toll-like receptors (TLRs) that recognize pathogen-associated molecular patterns (PAMPs) causes the initial immune response. TLR7 is an endosomal receptor activated by viral ssRNAs and synthetic ligands. It is expressed in different types of immune cells, as well as epithelial and tumor cells. The aim of this research was to determine the effects of TLR7 ligand (resiquimod and imiquimod) and cytostatic (cisplatin, carboplatin, paclitaxel) combined therapy on H1299 human metastatic cell lineage. We have shown the presence of TLR7 mRNA and proteins expression in H1299 cells using RT-qPCR and Western blot. We have shown that imiquimod in combination with cisplatin and paclitaxel significantly reduces H1299 cell viability, while combined treatment with resiquimod had low cytotoxic effect.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:217:798897
Study programmeTitle: Molecular Biology
Study programme type: university
Study level: graduate
Academic / professional title: magistar/magistra molekularne biologije (magistar/magistra molekularne biologije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Embargo expiration date: 2021-02-24
Terms of useLicence In copyright icon
Created on2020-06-09 10:17:54